Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
复制标题
DOI：
10.1038/nrc4019
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Balkwill FR
中科院分区：
文献类型：
--
作者：
Bowtell DD;Böhm S;Ahmed AA;Aspuria PJ;Bast RC Jr;Beral V;Berek JS;Birrer MJ;Blagden S;Bookman MA;Brenton JD;Chiappinelli KB;Martins FC;Coukos G;Drapkin R;Edmondson R;Fotopoulou C;Gabra H;Galon J;Gourley C;Heong V;Huntsman DG;Iwanicki M;Karlan BY;Kaye A;Lengyel E;Levine DA;Lu KH;McNeish IA;Menon U;Narod SA;Nelson BH;Nephew KP;Pharoah P;Powell DJ Jr;Ramos P;Romero IL;Scott CL;Sood AK;Stronach EA;Balkwill FR
高级别浆液性卵巢癌(HGSOC)占卵巢癌死亡的70%-80%，总体生存率几十年来没有明显变化。在这篇评论文章中，我们概述了一系列研究优先事项，我们相信这些优先研究将减少这种疾病的发病率，并改善妇女的预后。HGSOC的这一“路线图”是在2015年1月的一次卵巢癌行动会议上经过广泛讨论后确定的。
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This ‘roadmap’ for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.